Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study
| Autor: | Yasuo Kurimoto, Mamoru Uenishi, Shigeru Honda, Michiko Mandai, Takafumi Hirashima, Shunichiro Nakai, Yoshiko Matsumoto, Hideyasu Oh, Akio Oishi, Noriko Miyamoto |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Vascular Endothelial Growth Factor A
medicine.medical_specialty Visual acuity Time Factors medicine.medical_treatment Visual Acuity Photodynamic therapy Angiogenesis Inhibitors 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Polyps Ophthalmology Ranibizumab Medicine Initial treatment Humans In patient 030212 general & internal medicine Retrospective Studies Photosensitizing Agents business.industry Choroid Macular atrophy Verteporfin Long term results Choroid Diseases Sensory Systems Treatment Outcome Photochemotherapy Injections Intravenous Intravitreal Injections 030221 ophthalmology & optometry medicine.symptom Intravitreal ranibizumab business Tomography Optical Coherence medicine.drug Follow-Up Studies |
| Zdroj: | The British journal of ophthalmology. 103(6) |
| ISSN: | 1468-2079 |
| Popis: | Background/aimWe previously reported that ranibizumab performed better on visual prognosis than photodynamic therapy (PDT) in a Ranibizumab (Lucentis)AndPhotodynamicTherapyOnPolypoidal choroidal vasculopathy (LAPTOP) study. To determine if the first-choice treatment, either PDT or intravitreal ranibizumab, has a long-term effect in patients with polypoidal choroidal vasculopathy (PCV).MethodsWe reviewed medical records of patientsrandomised to either PDT (29 eyes) or ranibizumab (27 eyes) from July 2009 to June 2011 in LAPTOP study. Retreatment or switching to other treatments were at the investigator’s discretion after release from the 2-year LAPTOP study up to 5years. We evaluated visual acuity (VA), continuity of initial treatment, percentage of dry macula achievement and macular atrophy at 5 years.ResultsThe logarithm of minimal angle of resolution VA was 0.56 in the PDT and 0.44 in the ranibizumab groups at baseline (p=0.101) and was 0.55 and 0.28 at 5years, respectively (p2, respectively (p=0.155).ConclusionsThe better VA in the initial ranibizumab group compared with the PDT group at 2 years was retained at the 5-year follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|